Vulvovaginal atrophy

Mayo Clinic Proceedings

Volumn 85, Issue 1, 2010, Pages 87-94

  Mac Bride, Maire B ^a   Rhodes, Deborah J ^a   Shuster, Lynne T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANASTROZOLE; AROMATASE INHIBITOR; CALCITRIOL; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GESTAGEN; GONADORELIN AGONIST; PHYTOESTROGEN; PLACEBO; RALOXIFENE; SILICONE; TAMOXIFEN;

ADJUVANT THERAPY; ADVANCED CANCER; ALTERNATIVE MEDICINE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVOR; CLINICAL FEATURE; CLINICAL TRIAL; CONTACT DERMATITIS; DIAGNOSTIC TEST; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; HEMATURIA; HISTOPATHOLOGY; HUMAN; IRRITANT DERMATITIS; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LOW DRUG DOSE; MOLECULAR MECHANICS; NEURODERMATITIS; NOCTURIA; OVARY INSUFFICIENCY; PAGET SKIN DISEASE; PATHOPHYSIOLOGY; PETECHIA; PH MEASUREMENT; POSTMENOPAUSE; PRECANCER; PREVALENCE; RECURRENT INFECTION; REVIEW; SOYBEAN; TRANSDERMAL PATCH; TREATMENT OUTCOME; TRICHOMONIASIS; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; UTERINE CERVIX; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA DISEASE; VAGINA MUCOSA; VAGINA PAIN; VAGINA RING; VAGINAL DRYNESS; VAGINAL PRURITUS; VAGINITIS; VULVA CANCER; VULVA TUMOR;

EID: 73649135769     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0413     Document Type: Review

References (51)

1. Moreira ED, Glasser DB, Nicolosi A, Nicolosi A, Duarte FG, Gingell C; GSSAB Investigators' Group. Sexual problems and help-seeking behavior in adults in the United Kingdom and continental Europe. BJU Int. 2008;101(8):1005-1011.
2. Simon JA, Komi J. Postmenopausal women's attitudes: vulvovaginal atrophy and its symptoms [abstract LB-10]. Menopause. 2007;14(6):1107.
3. Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984;63(3):257-260.
4. Dennerstein L, Dudley E, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obst Gynecol. 2000;96(3):351-358.
5. Stadberg E, Mattsson LA, Milsom I. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. Acta Obstet Gynecol Scand. 1997;76(5):442-448.
6. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and life-style factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000;152(5):463-473.
7. Wilbur J, Miller AM, Montgomery A, Chandler P. Sociodemographic characteristics, biological factors, and symptom reporting in midlife women. Menopause. 1998;5(1):43-51.
8. Crandall C, Petersen L, Ganz P, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause. 2004;11(5):519-530.
9. Williams RE, Kalilani L, DiBenedetti DB, Zhou X. Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007;58(4):348-358.
10. Cella D, Fallowfield L, Barker P, Cuzick J, Howell A; ATAC Trialists A9 Group. Quality of life of postmenopausal women in the ATAC ("Arimidex" , tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100(3):273-284.
11. North American Menopause Society (NAMS). Menopause Practice: A Clinician's Guide. 3rd ed. Mayfield Heights, OH: North American Menopause Society; 2007.
12. Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol. 2004;190:1272-1277.
13. Brown KH, Hammond CB. Urogenital atrophy. Obstet Gynecol Clin North Am. 1987;14(1):13-32.
14. Semmens JP, Wagner G. Estrogen deprivation and vaginal function in postmenopausal women. JAMA. 1982;248(4):445-448.
15. Gupta P, Özel B, Stanczyk FZ, Felix JC, Mishell DR Jr. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Menopause. 2008;15(1):94-97.
16. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol. 2001;63:165-192.
17. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci. 1997;314(4):228-231.
18. Sultana CJ, Walters MD. Estrogen and urinary incontinence in women. Maturitas. 1994;20(2-3):129-138.
19. Barlow DH, Cardoza LD. Francis RM, et al. Urogenital ageing and its effect on sexual health in older British women. Br J Obstet Gynaecol. 1997;104(1):87-91.
20. Greendale GA, Zibecchi L, Peterson L, Ouslander JG, Kahn B, Ganz PA. Development and validation of a physical examination scale to assess vaginal atrophy and inflammation. Climateric. 1999;2(3):197-204.
21. O'Connell TX, Nathan LS, Satmary WA, Goldstein AT. Non-neoplastic epithelial disorders of the vulva. Am Fam Physician. 2008;77(3):321-326.
22. North American Menopause Society. The role of local vaginal estrogens for the treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3):357-369.
23. Suckling J, Kennedy R, Lethaby A. Local oestrogens for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;(4):CD001500.
24. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency - a pharmacokinetic and pharmacodynamic study. Maturitas. 1992;15(2):121-127.
25. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99(4):556-562.
26. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause. 2009;(16):30-36.
27. Notelovitz M. Urogenital aging: solutions in clinical practice. Int J Gynaecol Obstet. 1997;59(suppl 1):S35-S39.
28. Steinauer JE, Waetjen LE, Vittinghoff E, et al. Postmenopausal hormone therapy; does it cause incontinence? Obstet Gynecol. 2005;1069(5, pt 1):940-945.
29. Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935-948.
30. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol. 1999;17(5):1488-1492.
31. Nystedt M, Berglund G, Bolund C, Brandberg Y, Fornander T, Rutqvist LE. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer: self-rated physiological effects and symptoms. Acta Oncologica. 2000;39(8):959-968.
32. Lahti E, Vuopala S, Kauppila A, Blanco G, Ruokonen A, Laatikainen T. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen. Gynecol Oncol. 1994;55(3, pt 1):410-414.
33. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998;16(2):501-514.
34. Premkumar A, Venzon DJ, Avila N, et al. Gynecologic and hormonal effects of raloxifene in premenopausal women. Fertil Steril. 2007;88(6):1637- 1644.
35. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999;93(4):558-565.
36. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23(28):6931-6940.
37. Mourits MJ, Böckermann I, de Vries EG, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer. 2002;86(10):1546-1550.
38. Fornander T, Rutqvist L, Wilking N. Effects of tamoxifen on the female genital tract. Ann N Y Acad Sci. 1991;622:469-476.
39. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6)466-472.
40. Higgins MJ, Davidson NE. What is the current status of ovarian suppression/ ablation in women with premenopausal early-stage breast cancer? Curr Oncol Rep. 2009;11(1):45-50.
41. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584-587.
42. Morali G, Polatti F, Metelitsa EN, Mascarucci P, Maqnani P, Marrè GB. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. Arzneimittelforschung. 2006;56(3):230-238.
43. Yildirim B, Kaleli B, Düzcan E, Topuz O. The effects of postmenopausal vitamin D treatment on vaginal atrophy. Maturitas. 2004;49(4):334-337.
44. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause. 2008;15(1):51-58.
45. Simon JA. Vulvovaginal atrophy: new and upcoming approaches [editorial]. Menopause. 2009;16(1):5-7.
46. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111(1):67-76.
47. Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause. 2004;11(1):49-56.
48. Dugal R, Hesla K, Sørdal T, Aase K, Lilleeidet O, Wickstrøm E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand. 2000;79(4):293-297.
49. Raz R. Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329:753-756.
50. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet. 1999;353(9167):1824- 1828.
51. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet [published correction appears in Obstet Gyencol. 2008;112(6):1392]. Obstet Gynecol. 2008;112(5):1053-1060.